Literature DB >> 35430703

NSG-70, a new glioblastoma cell line with mixed proneural-mesenchymal features, associates NOTCH1-WNT5A signaling with stem cell maintenance and angiogenesis.

Divya Kumari Singh1, Pavan Kumar Mysuru Shivalingappa1, Aman Sharma1,2, Abir Mondal1, Dattatraya Muzumdar3, Anjali Shiras1, Sharmila A Bapat4.   

Abstract

BACKGROUND: Glioblastoma initiation and progression is believed to be driven by Glioma stem cells (GSCs). Activation of NOTCH1 and WNT, and more recently, non-canonical WNT5A signaling, has been demonstrated to regulate self-renewal and differentiation of the GSCs crucially. High expression levels of NOTCH1 and WNT in GBM tumors contribute to the sustenance of GSCs and mediate characteristic phenotypic plasticity, which is reflected by the different subtypes and tremendous intra-tumor heterogeneity. However, the coregulation of NOTCH1 and WNT5A is not well understood. Here, we studied the role of these molecules in regulating the characteristics of different GSC subtypes.
METHODS: We established a novel GSC-enriched cell model, referred to as NSG-70, from a patient with recurrent GBM. NSG-70 cells harbor a unique cytogenetic feature, viz. isochromosome 9q. At the same time, its expression profiles indicate that it is a mixed lineage comprising proneural and mesenchymal subtypes. We examined the relevance of NOTCH1 and WNT5A signaling and their coordinated action in GBM using these cells and other patient-derived models representing different GSC subtypes.
RESULTS: Our data revealed that the downregulation of NOTCH1 resulted in the suppression of stem cell and mesenchymal markers and significantly reduced the levels of WNT5A. NOTCH1 knockdown also led to a notable reduction in the vasculogenic mimicry of GSCs. Interestingly, knockdown of WNT5A exhibited similar effects and drove quiescent GSC towards proliferation. In a complementary manner, ectopic expression of WNT5A or rhWNT5A treatment rescued the effects of NOTCH1 knockdown.
CONCLUSION: The resistance of GSCs towards conventional therapies in part due to subtype interconversion demands therapies targeting specific GSC subtype. Our study suggests the need for a combinatorial approach that could effectively target the NOTCH1-WNT5A signaling axis toward eliminating GSCs.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Glioblastoma; Glioma stem cells; Glioma subtypes; NOTCH1 signaling; Tumor heterogeneity; WNT5A signalling

Mesh:

Substances:

Year:  2022        PMID: 35430703     DOI: 10.1007/s11060-022-04002-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

1.  Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition.

Authors:  Ulf D Kahlert; Donata Maciaczyk; Soroush Doostkam; Brent A Orr; Brian Simons; Tomasz Bogiel; Thomas Reithmeier; Marco Prinz; Jörg Schubert; Gabriele Niedermann; Thomas Brabletz; Charles G Eberhart; Guido Nikkhah; Jaroslaw Maciaczyk
Journal:  Cancer Lett       Date:  2012-05-28       Impact factor: 8.679

2.  Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression.

Authors:  Xiuxing Wang; Briana C Prager; Qiulian Wu; Leo J Y Kim; Ryan C Gimple; Yu Shi; Kailin Yang; Andrew R Morton; Wenchao Zhou; Zhe Zhu; Elisabeth Anne Adanma Obara; Tyler E Miller; Anne Song; Sisi Lai; Christopher G Hubert; Xun Jin; Zhi Huang; Xiaoguang Fang; Deobrat Dixit; Weiwei Tao; Kui Zhai; Cong Chen; Zhen Dong; Guoxin Zhang; Stephen M Dombrowski; Petra Hamerlik; Stephen C Mack; Shideng Bao; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2018-04-05       Impact factor: 24.633

3.  Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3.

Authors:  Ping Mao; Kaushal Joshi; Jianfeng Li; Sung-Hak Kim; Peipei Li; Lucas Santana-Santos; Soumya Luthra; Uma R Chandran; Panayiotis V Benos; Luke Smith; Maode Wang; Bo Hu; Shi-Yuan Cheng; Robert W Sobol; Ichiro Nakano
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

4.  Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin.

Authors:  Claudio Lottaz; Dagmar Beier; Katharina Meyer; Praveen Kumar; Andreas Hermann; Johannes Schwarz; Markus Junker; Peter J Oefner; Ulrich Bogdahn; Jörg Wischhusen; Rainer Spang; Alexander Storch; Christoph P Beier
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

5.  Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.

Authors:  Jun Sunayama; Ken-Ichiro Matsuda; Atsushi Sato; Ken Tachibana; Kaori Suzuki; Yoshitaka Narita; Soichiro Shibui; Kaori Sakurada; Takamasa Kayama; Arata Tomiyama; Chifumi Kitanaka
Journal:  Stem Cells       Date:  2010-11       Impact factor: 6.277

Review 6.  Glioblastoma cancer stem cell biology: Potential theranostic targets.

Authors:  Farzaneh Sharifzad; Saeid Ghavami; Javad Verdi; Soura Mardpour; Mahsa Mollapour Sisakht; Zahra Azizi; Adeleh Taghikhani; Marek J Łos; Esmail Fakharian; Marzieh Ebrahimi; Amir Ali Hamidieh
Journal:  Drug Resist Updat       Date:  2019-03-08       Impact factor: 18.500

7.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

Review 8.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.

Authors:  Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Rev Cancer       Date:  2008-09-11       Impact factor: 60.716

9.  Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors.

Authors:  Wei Zhou; Jingzi Hu; Haimei Tang; Da Wang; Xuefeng Huang; Chao He; Hongbo Zhu
Journal:  BMC Cancer       Date:  2011-11-14       Impact factor: 4.430

10.  Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs.

Authors:  Ahmad R Safa; Mohammad Reza Saadatzadeh; Aaron A Cohen-Gadol; Karen E Pollok; Khadijeh Bijangi-Vishehsaraei
Journal:  Genes Dis       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.